Investor Information
TheraGenetics is a privately held, personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of CNS disorders, bringing the right medicine to the right patient.
TheraGenetics is based in London, England; with funding provided by a number of investors including:
Swarraton Partners Ltd.
www.swarraton.comSwarraton Partners is a venture capital firm investing in early stage technology companies based on world class European research.
IP Group Plc.
www.ipgroupplc.comIP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions.
At the time that the Company was founded in 2001, it had a single university partnership (the University of Oxford). Today it has long-term partnerships with ten universities in total in the UK. As at 31 December 2006, 53 portfolio companies had been created from these partnerships.
Tudor Capital
Tudor Capital is part of the The Tudor Group, which currently manages $17.7 billion, and is involved in active trading, investing and research in the global equity, debt, currency and commodity markets.
Javelin General Partner (Kinetique) Limited
www.javelin-ventures.comJavelin Ventures specialises in investing in early stage technology companies. They manage the Kinetique Biomedical Seed Fund and the Heptagon Proof of Concept Fund.
The Kinetique Biomedical Seed Fund is one of the few specialist University Challenge Seed Funds. Kinetique invests in technologies relating to the biomedical sciences - this includes the development of therapeutics, drug delivery systems, diagnostics, devices, biomaterials and IT related to healthcare.
For further information, please contact: